POL6014

Indicaton

Cystic Fibrosis

Therapeutic indications

Respiratory

Type of product

Table

Phase

Phase I completed
Partnering status

Partnered
Partner

Santhera

You may also be interested in

OligoPhore / SemaPhore Peptide-Based RNA Delivery Platforms

Delivers siRNA, antisense oligonucleotides, mRNA and other mRNA modalities to extrahepatic tissues - demonstrated across various indications in oncology (e.g. PDAC, breast cancer, ovarian cancer, lung cancer, melanoma, ATLL, TME), and inflammatory / autoimmune diseases (e.g. OA, RA, enterocolitis), CV (e.g. atherosclerosis, aortic aneurysm)

Discovery

POL6014

Cystic fibrosis (CF) and other neutrophilic pulmonary diseases

Phase I started

A2AR positive allosteric modulator

Multiple, see therapeutic areas. GI indications also relevant.

Discovery